Clinical Trials
96 trialsTreat Primary and Metastatic Liver Tumors
Methodist Health System
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
University of Florida
PRISM
Weill Medical College of Cornell University
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Shanghai Zhongshan Hospital
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Medical University of South Carolina
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
Fifth Affiliated Hospital, Sun Yat-Sen University
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Children's National Research Institute
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
University of Arizona
Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors
University of Cincinnati
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
M.D. Anderson Cancer Center
HCC
Abramson Cancer Center at Penn Medicine
Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma
Mayo Clinic
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
University of Rochester
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Sun Yat-sen University
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
M.D. Anderson Cancer Center
Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
Tokyo Medical and Dental University
Y-90 Versus SBRT for Inoperable HCC
OHSU Knight Cancer Institute
FDGal PET/CT to Detect Hepatocellular Carcinoma
British Columbia Cancer Agency
LIDA-ADJ
University Hospital, Montpellier
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
A Study to Evaluate Vaccines Against COVID-19 in the Real World
Humanity & Health Medical Group Limited
ECHAPS
University Hospital, Grenoble
BCAA in HCC
Louisiana State University Health Sciences Center in New Orleans
Adjuvant Therapy With Anlotinib for HCC
Shanghai Zhongshan Hospital
Microwave Ablation of Resectable Liver Tumors
St. Joseph Hospital of Orange
Irreversible Electroporation of Unresectable Liver Tumors
Aalborg University Hospital
TheraBionics
Wake Forest University Health Sciences
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Zhejiang University
Improving CBCT for Liver IG-SBRT Using Gadoxetate Disodium
Nova Scotia Health Authority
IRAL
Karolinska Institutet
Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Intrahepatic Vessels
National Taiwan University Hospital
Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry
Rush University Medical Center
The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors
National Taiwan University Hospital
RADBRI
University Health Network, Toronto
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
Jonsson Comprehensive Cancer Center
CAR-T Cell Immunotherapy for HCC Targeting GPC3
Fuda Cancer Hospital, Guangzhou
STOP-HCC
University of Texas Southwestern Medical Center
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
Baylor College of Medicine
TACERT
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation
Zhejiang University
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Sun Yat-sen University
Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma
Shanghai Proton and Heavy Ion Center
LD-FOX4/HCC
Guangxi Medical University
Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
Guangxi Medical University
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
Guangxi Medical University
Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
Sun Yat-sen University
Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization
University of Southern California